GP350 AS A NOVEL VACCINE PROTEIN CARRIER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 实验目的：在我们的第一组实验中，我们用吸附在明矾中的不同剂量的PPS14-gp350结合物免疫年轻成年恒河猴，并在第28天和第42天加强免疫。免疫猴子即使用最低剂量的PPS14-gp350也能产生可检测到的抗PPS14和抗gp350的抗体滴度。作为本实验的后续工作，我们想要直接比较不同剂量的明矾吸附的未结合或PPS14结合的单体gp350的能力：a)诱导一次、二次和三次血浆中抗gp350滴度并诱导亲和力成熟(通过ELISA检测)，b)诱导EBV中和抗体(通过体外B细胞转化和ELISA中和实验检测)以及c)激发特异性CD4+T细胞(通过体外再刺激实验检测)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose of the experiment: In our first set of experiment, we immunized young adult rhesus monkeys with varying doses of PPS14-gp350 conjugate adsorbed in alum and boosted similarly on day 28 and 42. Immune monkeys generated detectable IgG anti-PPS14 and anti-gp350 titer even with lowest dose of PPS14-gp350. As a follow up of this experiment, we would like to directly compare the ability of varying doses of alum-adsorbed unconjugated or PPS14-conjugated monomeric gp350 to: a) elicit primary, secondary, and tertiary plasma IgG anti-gp350 titers and induce affinity maturation as determined by ELISA, b) induce EBV-neutralizing antibody as determined by both an in vitro B cell transformation and ELISA neutralization assay and c) prime specific CD4+ T cells as determined by an in vitro re-stimulation assay.